Scancell Holdings plc (LON:SCLP – Get Free Report)’s share price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 14.26 and traded as low as GBX 9.70. Scancell shares last traded at GBX 9.80, with a volume of 906,720 shares.
Scancell Stock Down 0.5%
The company has a current ratio of 0.56, a quick ratio of 13.01 and a debt-to-equity ratio of -193.29. The firm has a 50-day moving average of GBX 10.31 and a two-hundred day moving average of GBX 14.26. The firm has a market cap of £104.64 million, a price-to-earnings ratio of -17.82 and a beta of 0.69.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Further Reading
- Five stocks we like better than Scancell
- These 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity Push
- Lennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing
- Priced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits
- These 3 Agentic AI Stocks Have More Than Hype Behind Their Growth Stories
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
